LENSAR(US:LNSR)2026-03-31 13:32Financial Data and Key Metrics Changes - The company reported total revenue of $16 million for Q4 2025, representing a 4% decline year-over-year, primarily due to lower system sales [18] - Full year 2025 revenue increased by 9% compared to 2024, with recurring revenue growing by 15% [20][21] - The gross margin for Q4 was 43%, slightly up from 42% in Q4 2024, while the full year gross margin was 46%, down from 48% in 2024 [22][23] Business Line Data and Key Metrics Changes - The installed base of ALLY systems grew to approximately 200, with a 48% year-over-year increase, and procedure volume increased by 20% year-over-year [22] - The company achieved a 23.4% procedure share in the U.S. by the end of 2025, up from 14% [10] - The company placed 15 ALLY systems in Q4 2025, contributing to a total of 206,000 procedures globally for the year [22] Market Data and Key Metrics Changes - U.S. ALLY sales increased by one system to 12 in Q4 2025, while international sales dropped significantly from 10 systems in Q4 2024 to just one in Q4 2025 [18][19] - The company noted that the uncertainty surrounding the acquisition negatively impacted international business expansion [13] Company Strategy and Development Direction - The company aims to focus on growing procedure volumes and recurring revenue through additional system placements and increased utilization of existing systems [15] - The strategy includes re-engaging with distributors and stakeholders to regain momentum lost during the acquisition process [14] - The company plans to explore new markets, including Australia and New Zealand, and expand its presence in Europe and Southeast Asia [50][55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to historical operating performance and emphasized the importance of rebuilding momentum over the next several quarters [9][61] - The company acknowledged the challenges faced during the acquisition process but highlighted the validation of its technology and market position [5][6] - Management expects to see gradual improvements in system sales and recurring revenue as distributors re-engage [20][42] Other Important Information - The company received a $10 million transaction deposit following the termination of the acquisition, which will enhance its cash position [8][17] - The company recorded $17.1 million in total acquisition costs in 2025, with a portion expected to be eliminated due to the termination of the merger [17] Q&A Session Summary Question: Can you elaborate on the distributor commentary and its impact on growth? - Management indicated that while conversations with distributors have been positive, it will take time to regain momentum in international markets due to previous uncertainties [29][32] Question: How should we think about the mix of capital placements versus lease-based placements? - Management noted that revenue recognition differs between U.S. and international sales, with a potential shift towards more lease-based placements in the U.S. [33][36] Question: Can you clarify the expected increase in operating expenses for 2026? - Management confirmed that cash-based operating expenses are expected to increase by 10%, excluding merger-related costs [37][38] Question: What is the outlook for U.S. procedure growth given recent trends? - Management reported that recurring revenue is becoming healthy, with expectations for continued growth in procedure volumes driven by the installed base [41][42] Question: Are there new market opportunities outside the U.S.? - Management expressed interest in exploring markets like Australia and New Zealand, as well as expanding in Europe and Southeast Asia [50][55]